Prospective case-control study.
Academic-affiliated assisted reproductive technology unit.
Fourteen PCOS and 14 matched non-PCOS control women undergoing COS.
Serum was collected on day 3 (baseline), day of hCG, and day of retrieval. Follicular fluid (FF) was collected on day of oocyte retrieval. ELISA was performed to determine TGF-¦Â1 and sENG protein levels.
Serum and FF levels of TGF-¦Â1 and sENG.
Serum TGF-¦Â1 did not change significantly during COS but was increased in PCOS compared with non-PCOS women on day 3 and days of hCG administration and oocyte retrieval. Serum sENG increased after hCG administration only in the non-PCOS control group. In addition, serum sENG was decreased in PCOS compared with non-PCOS control women on the days of hCG and retrieval. Accordingly, the bioavailability of TGF-¦Â1 (TGF-¦Â1/sENG ratio) was increased in women with PCOS compared with non-PCOS controls at all three time points. No differences in either factor were noted in FF between groups.
The increased TGF-¦Â1 bioavailability in PCOS is not only due to increased TGF-¦Â1 levels but also to decreased levels of its receptor, sENG. These data suggest that increased TGF-¦Â1 bioavailability may contribute to the pathogenesis of PCOS and its increased risk for ovarian hyperstimulation.